New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 1, 2013
06:20 EDTINFI, ARIA, GILDGilead seeks more blood cancer drug deals, Bloomberg reports
Gilead Sciences (GILD) has spent $1.2B in two years to buy blood cancer drugs, and wants more, reports Bloomberg. Treatment for leukemia and other blood cancers is one of the fastest growing markets for cancer drugs. Gilead COO John Milligan said the company is eyeing possible new deals. They could include Ariad Pharmaceuticals (ARIA) and Infinity Pharmaceuticals (INFI), said Raghuram Selvaraju, at Aegis Capital Corp. Reference Link
News For GILD;ARIA;INFI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 17, 2015
07:36 EDTARIAARIAD presents updated clinical data on Brigatinib
Subscribe for More Information
April 15, 2015
16:01 EDTGILDOptions Update; April 15, 2015
iPath S&P 500 VIX Short-Term Futures down 49c to 21.90. Option volume leaders: AAPL NFLX C PBR KMI RIG MCP TWTR GILD BAC according to Track Data.
April 14, 2015
08:05 EDTINFIInfinity Pharmaceuticals names Sujay Kango as Chief Commercial Officer
Subscribe for More Information
April 13, 2015
16:01 EDTGILDOptions Update; April 13, 2015
Subscribe for More Information
14:20 EDTARIANHS Scotland accepts ARIAD's Iclusig for use
Subscribe for More Information
09:34 EDTGILDActive equity options trading on open
Subscribe for More Information
April 10, 2015
16:05 EDTGILDOptions Update; April 10, 2015
Subscribe for More Information
April 9, 2015
06:12 EDTGILDSovaldi prices causes Medicaid spending for hepatitis C drugs to soar, WSJ says
Subscribe for More Information
April 7, 2015
17:58 EDTGILDGilead submits NDA for investigational combination for treatment of HIV-1
Subscribe for More Information
16:00 EDTGILDOptions Update; April 7, 2015
Subscribe for More Information
April 6, 2015
09:22 EDTARIAOn The Fly: Pre-market Movers
HIGHER: Uniqure (QURE), up 44.2% following strategic collaboration with Bristol-Myers (BMY)... Cytori Therapeutics (CYTX), up 22.4% after Lorem Vascular receives regulatory clearance in China... Curis (CRIS), up 8.5% after FDA grants orphan drug designation to CUDC-907 for the treatment of Diffuse Large B-Cell Lymphoma... Capnia (CAPN), up 5.9% after being awarded a $220,000 NIH grant... Tesla (TSLA), up 3.8% after reporting first quarter deliveries up 55% to 10,030 cars... Ariad (ARIA), up 3.4% following approval of Iclusig in Canada... Lumber Liquidators (LL), up 3.1% after being upgraded to Outperform from Market Perform at Raymond James. LOWER: Magnum Hunter (MHR), down 8.9% after being downgraded to Hold from Buy at Wunderlich... Herbalife (HLF), down following CNBC report that federal law enforcement agencies contacted the company regarding its business practices... Qualcomm (QCOM), down 2.2% following a Wall Street Journal report that the Samsung (SSNLF) Galaxy S6 did not have a Qualcomm LTE modem... Skyworks (SWKS), down 2.1% after being downgraded to Equal Weight from Overweight at Stephens.
07:36 EDTGILDGilead Q1 HCV revenue poised to beat expectations, says RBC Capital
After analyzing weekly prescription data, RBC Capital believes that Gilead's weekly hepatitis C prescriptions are tracking towards $3.5B-$3.6B of revenue from hepatitis C drugs for Q1, versus the consensus outlook of about $2.6B. The firm keeps an Outperform rating on Gilead.
07:36 EDTARIAARIAD announces approval of Iclusig in Canada
Subscribe for More Information
April 5, 2015
14:43 EDTGILDActavis seeks FDA approval to market generic version of Gilead's Letairis
Actavis (ACT) on Friday, confirmed that it has filed an Abbreviated New Drug Application with the FDA seeking approval to market Ambrisentan Tablets, 5 mg and 10 mg. Actavis' ANDA product is a generic version of Gilead Science's (GILD) Letairis, which is a treatment for pulmonary arterial hypertension. Gilead Sciences and Royalty Pharma Collection Trust filed suit against Actavis on April 1, in the U.S. District Court for the District of Delaware seeking to prevent Actavis from commercializing its ANDA product prior to the expiration of U.S. Patent number RE42,462. The lawsuit was filed under the provisions of the Hatch-Waxman Act, resulting in a stay of final FDA approval of Actavis' ANDA for up to 30 months from the date the plaintiffs received notice of Actavis' ANDA filing or until final resolution of the matter before the court, whichever occurs sooner, subject to any other exclusivities. Based on available information, Actavis believes it may be a "first applicant" to file an ANDA for the generic version of Letairis and, should its ANDA be approved, may be entitled to 180 days of generic market exclusivity. For the 12 months ending December 31, Letairis had global sales of approximately $595M, according to Gilead.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use